MJManja Jargosch

Manja Jargosch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manja Jargosch has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Proliferation-associated protein 2G4 promotes keratinocyte proliferation and survival in psoriasis

    by Theresa Raunegger, Sophia Wasserer, Jessica Eigemann, Christina Hillig, Görkem Aydin, Nils Kurzen, Carsten B Schmidt-Weber, Michael P Menden, Natalie Garzorz-Stark, Inga Weßels, et al.

    Psoriasis is a non-communicable inflammatory skin disease that affects approximately 2%–3% of the world’s population. Given its high impact on quality of life and the fact that a subset of patients exhibits suboptimal or secondary loss of response to current treatments, identifying new therapeutic strategies is crucial. Proliferation-associated protein 2G4 (PA2G4) is a transcription factor that has been exclusively studied in cancer research, where it promotes cell growth and enhances tumourigenesis by inhibiting apoptosis. However, its role in inflammatory skin diseases remains largely unknown. This study focused on the pathophysiological and immunological functions of PA2G4 in psoriasis and evaluated its potential as a therapeutic target. Bulk, single-cell, and spatial RNA sequencing combined with immunohistochemistry were used to assess PA2G4 expression in psoriatic skin compared with that in non-lesional controls. Functional studies were performed in primary human keratinocytes and reconstructed human epidermis (RHE) models using the CRISPR/Cas9-mediated knockout (KO) of PA2G4 and pharmacological inhibition of PA2G4 with the small-molecule WS6. The regulatory effects of PA2G4 on cellular processes, such as proliferation, differentiation, and survival, were investigated using RNA-seq, western blot analysis, scratch assays, and annexin V staining. PA2G4 was highly abundant in psoriasis, and its expression was predominantly restricted to basal proliferating keratinocytes. Its gene expression is positively correlated with psoriasis severity, the degree of acanthosis, neutrophil infiltration, and genes which are upregulated in psoriasis. PA2G4 KO in primary human keratinocytes activated differentiation pathways while suppressing proliferation pathways, resulting in the downregulation of proliferation- and inflammation-related genes (e.g. MKI67, IL20, VEGFA, and HIF1A) and the upregulation of differentiation and cell adhesion markers (e.g. KRT6C, LCE2C, and DSG4). Functionally, the PA2G4 KO reduced keratinocyte proliferation in scratch assays, attenuated interleukin-22-induced acanthosis in RHE models, and promoted keratinocyte death. Pharmacological inhibition of PA2G4 using the small-molecule inhibitor WS6 similarly downregulated genes associated with proliferation and cell survival. PA2G4 could promote keratinocyte hyperproliferation and survival in psoriasis, thereby critically influencing epidermal homeostasis. Therefore, inhibition of PA2G4 may represent a new treatment option for psoriasis.


  • Open Access

    Immunopeptidome analysis reveals SERPINB3 as an autoantigen driving eczematized psoriasis

    by Manja Jargosch, Jomy Kuruvila, Emanuele Scala, Johannes Grosch, Jessica Eigemann, Sophia Wasserer, Shalva Lekiashvili, Nico Trautwein, Daniel Johannes Kowalewski, Alexander Böhner, et al.

    Psoriasis (Pso) is a chronic inflammatory skin disease driven by T helper 17 (T H 17) cells, with several clinical subtypes. While self-reactive immune responses have been observed, the role of autoantigens in Pso remains unclear. Using immunopeptidomics, we identified serpin family B member 3 (SERPINB3) and SERPINB4 as candidate autoantigens in Pso skin. In a mouse model, the SERPINB3 ortholog Serpinb3b enhanced inflammation, promoted tissue-resident memory T cells, and skewed immunity toward a T H 2 phenotype. In humans, SERPINB3 reactivity was specifically associated with “eczematized psoriasis” (EczPso), a subtype marked by T H 2/T H 17 immune signatures. SERPINB3 protein was enriched in EczPso lesions and highly secreted by keratinocytes under combined T H 2/T H 17 stimulation. Lesional T cells from EczPso—but not from eczema or classical plaque Pso—proliferated in response to SERPINB3 and induced EczPso-like features in a skin model. Our findings identify SERPINB3 as an autoantigen driving a distinct Pso subtype, supporting more precise diagnosis and therapy.


  • Open Access

    Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus

    by Sophia Wasserer, Peter Seiringer, Nils Kurzen, Manja Jargosch, Jessica Eigemann, Görkem Aydin, Theresa Raunegger, Carsten B Schmidt-Weber, Stefanie Eyerich, Tilo Biedermann, et al.

    Background: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease with various clinical subtypes. Although its pathogenesis is not yet fully understood, T-cell-mediated autoimmunity and elevated levels of type I interferons (IFNs) are two major factors that contribute to the development of cutaneous lesions. Type I IFNs transduce their signal via tyrosine kinase 2 (TYK2). Objectives: To investigate the impact of TYK2 signalling in preclinical models of CLE. Methods: CLE skin biopsies were investigated by RNA sequencing (RNAseq) and immunohistochemistry. T cells isolated from CLE skin biopsies (lesional T cells) were restimulated with anti-CD3/anti-CD28 and cytokine release was quantified by enzyme-linked immunosorbent assay and Luminex®. Primary human keratinocytes and three-dimensional skin models were stimulated with IFN-α or lesional T-cell supernatant in the presence or absence of the TYK2 inhibitor deucravacitinib, followed by RNAseq. Skin biopsies from patients with different CLE subtypes were treated ex vivo with deucravacitinib followed by real-time quantitative polymerase chain reaction. Results: Bulk RNAseq revealed a strong correlation between TYK2 and interface dermatitis, a histological hallmark of CLE. Immunohistochemistry confirmed a high abundance of TYK2 in different CLE subtypes. Inhibiting TYK2 reduced inflammation and normalized epidermal impairments in primary human keratinocytes, reconstructed human epidermis and CLE T cells. Ex vivo TYK2 inhibition in CLE skin biopsies reduced IFN response and necroptosis-related gene expression. Finally, four patients with different therapy-refractory subtypes of CLE (acute, subacute, chronic discoid, chilblain CLE) were successfully treated with deucravacitinib. Conclusions: IFN-α and T-cell-derived cytokines both contribute to skin inflammation in CLE. TYK2 inhibition is a promising approach for different subtypes of CLE as it controls inflammation in various preclinical models and patients with CLE who are refractory to treatment.


  • The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2/TH17 immune response

    by Alexander Böhner, Manja Jargosch, Nikola S. Müller, Natalie Garzorz-Stark, Caroline Pilz, Felix Lauffer, Rosi Wang, Sophie Roenneberg, Alexander Zink, Jenny Thomas, et al.


  • Open Access

    Gene Expression–Based Molecular Test as Diagnostic Aid for the Differential Diagnosis of Psoriasis and Eczema in Formalin-Fixed and Paraffin-Embedded Tissue, Microbiopsies, and Tape Strips

    by Felix Fischer, Anais Doll, Deniz Uereyener, Sophie Roenneberg, Christina Hillig, Lucca Weber, Verena Hackert, Martin Meinel, Ali Farnoud, Peter Seiringer, et al.


  • Open Access

    Nuclear Factor of Activated T Cells Regulates the Expression of Interleukin-4 in Th2 Cells in an All-or-none Fashion

    by Juliana Köck, Stephan Kreher, Katrin Lehmann, René Riedel, Markus Bardua, Timo Lischke, Manja Jargosch, Claudia Haftmann, Hanna Bendfeldt, Farahnaz Hatam, et al.